2.5. Overexpression of PTK2B or LYN in Cytogenetic IR-AML Patients with Non-Favorable FLT3/NPM1 Combinations Is as Good in Prognosticating Survival or Recurrence as the Favorable FLT3/NPM1 Combination. This evidence concerns the gene FLT3 and acute myeloid leukemia.